Obstet Med. 2024 Jul 25:1753495X241263135. doi: 10.1177/1753495X241263135. Online ahead of print.
ABSTRACT
BACKGROUND: Transthoracic echocardiography, a validated tool for risk assessment in non-pregnant population with sickle cell disease (SCD), uses tricuspid regurgitant velocity (TRV) over 2.5 m/s is an independent mortality risk factor. Its applicability in obstetrics lacks sufficient evidence.
METHODS: In this multicenter retrospective cohort study across five tertiary centers, we aimed to validate TRV as a determinant of increased maternal and fetal risk. Data was collected on 93 women and included 21 patients with TRV of at least 2.5 m/s. The maternal primary composite outcome included occurrence of vaso-occlusive crisis, acute chest syndrome, gestational hypertension, preeclampsia, and mortality. The fetal primary composite outcome comprised perinatal mortality, premature delivery, reduced birth weight, and fetal distress.
RESULTS: Adverse maternal and fetal events arose in both groups with no statistical difference.
CONCLUSION: This study cannot support TRV of 2.5 m/s or more as an independent predictor of adverse obstetric outcomes among women with SCD.
PMID:39553170 | PMC:PMC11563517 | DOI:10.1177/1753495X241263135
